An observational study in Oligohydramnios, sponsored by Rambam Health Care Campus. Completed at 1 site in Israel. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2022-04-20.
Sponsored by Rambam Health Care Campus · Observational
The current study is based on the use of transvaginal sonography in the evaluation of oligohydramnios. Patients will be recruited after amniotic fluid index evaluation according to transabdominal sonography. After obtaining informed consent, transvaginal sonography will be used to evaluate and measure a possible amniotic fluid pocket that may precede the fetal presenting part.
Background Normal amniotic fluid volume varies across gestation (Ounpraseuth 2017). Abnormal amniotic fluid volume has been associated with a variety of adverse pregnancy outcomes (Shrem 2016). In clinical practice, the amniotic fluid volume is a component of the biophysical profile which provides information on fetal well-being.
Transabdominal ultrasound is used to assess quantitatively the amniotic fluid volume, most commonly by either the Amniotic Fluid Index (AFI) or the Maximum Vertical Pocket (MVP) methods.
The value of the AFI method has been questioned in several studies, which have shown that an abnormal test, low or high, is neither highly accurate nor predictive of adverse outcome. Many pregnancies with normal AFI will be falsely characterized as abnormal, and a large number with truly abnormal AFI will be missed (Magann 1994, Chauhan 1997).
The MVP measurement may be preferred over the AFI method. A 2008 systematic review of randomized trials found that use of the AFI increased the rate of diagnosis of oligohydramnios (RR 2.3), induction of labor (RR 2.1), and cesarean delivery for fetal distress (RR 1.5) (Nabhan 2008).
Rationale and Hypothesis of the Study Recently, our group observed that when transvaginal ultrasound is being performed to non-laboring pregnant women at term for other obstetrical indications, there is a large amniotic fluid pocket above the internal cervical os and below the fetal presenting part. Due to the unique location of this pocket, we hypothesized that transvaginal ultrasound may provide better information than transabdominal ultrasound on amniotic fluid volume, particularly in cases when suspecting abnormal low amniotic fluid volume.
Data Collection
Ultrasound Equipment and Safety Considerations In their 2011 statement, The International Society of Ultrasound in Obstetrics and Gynaecology (ISUOG) and World Federation of Ultrasound in Medicine and Biology (WFUMB) consider ultrasonography to be safe for use during clinical practice (ISUOG 2011).
Statistical analyses and sample size For sample size calculation, and given a 20% rate of induction of labor, of which 3% are due to abnormal low amniotic fluid volume (oligohydramnios), a sample size of 1000 women is required.
Feasibility of the Study Considering the high volume of maternal care here at Rambam Health Care Campus, and that every year there are around 5,000 births and nearly double routine cares, the recruitment process for the current study is feasible.
Expected Duration of the Study The recruitment for the study is expected to take place over 12 months with an additional 3-6 months after recruitment for data analysis before publication.
Funding Women will be recruited while approaching Rambam Health Care Campus for their routine obstetric care. Ultrasound examinations will be carried out using existing operational ultrasound equipments within the obstetric department at Rambam Health Care Campus. For both, the recruitment and the ultrasound examinations, no extra funding is currently required.
Public Health Interest Identifying new ultrasound variables that can assist in quantifying amniotic fluid volume, as the one suggested in the current study, is of great importance and may provide invaluable information into the overall future care and decision-making around the time of delivery, especially whether or not to induce labor in women with suspected oligohydramnios. Thus, it may assist in creating future recommendations for pregnant women and improved healthcare standards during the delivery process.
25 studies on the registry are indexed under Oligohydramnios; 5 are open to participants now.
Browse Oligohydramnios studies →Rambam Health Care Campus is the lead sponsor of 466 studies on the registry; 34 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Women who meet the above inclusion criteria will be asked to participate in the study and to provide a written informed consent. This study, under no circumstances, will alter the participants routine care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with an amniotic fluid index of between 5-24 centimeters according to transabdominal sonography.
Diagnostic Test: Transvaginal sonography
Patients with an amniotic fluid index of lss than 5 centimeters according to transabdominal sonography.
Diagnostic Test: Transvaginal sonography
Transvaginal sonography for the evaluation of an amniotic fluid pocket preceding the fetal presenting part.
Amniotic Fluid Fore-Pocket
Measurement of amniotic fluid pocket preceding fetal presenting part.
Time frame: Up to 30 minutes from the beginning of patient evaluation.
Mode of delivery
Vaginal delivery, vacuum assisted delivery, cesarean section.
Time frame: From time of induction up to 48 hours postpartum
pH level
Umbilical artery pH level
Time frame: From the time of delivery up to 30 days postpartum
1 minute Apgar score
Neonatal 1st minute Apgar score
Time frame: From the time of delivery up to 30 days postpartum
5 minute Apgar score
Neonatal 5th minute Apgar score
Time frame: From the time of delivery up to 30 days postpartum
Neonatal intensive care unit admission
Rate of neonatal intensive care unit admission
Time frame: From the time of delivery up to 30 days postpartum
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.